Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AAV2-GDNF

Phase 2Gene therapy

BBrain Neurotherapy Bio, Inc.

AAV2-GDNF is one of 86 biologic programs targeting Parkinson disease. It is currently in Phase 2.

3

Indications

3

Total Trials

3

Active Trials

85

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson DiseaseActive, not recruiting

Parkinson's DiseaseActive, not recruiting

Multiple System AtrophyActive, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Parkinson's DiseasePhase 1

Active, not recruiting

Multiple System AtrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Aricept

Namenda

Dostinex

Keppra

Nicorette

Buspar

Bristol-Myers Squibb

Avelox

Ritalin

Victoza

Nourianz

Kyowa Kirin Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Parkinson's Disease

NCT04167540

Q3 2028

Phase 1Active, not recruiting

Multiple System Atrophy

NCT04680065

Phase 2Active, not recruiting

Parkinson Disease

NCT06285643

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

GDNF Gene Therapy for Multiple System Atrophy

Active, not recruiting·BBrain Neurotherapy Bio, Inc.·Phase 1·NCT04680065·9 enrolled

Parkinson's Disease1 trial

GDNF Gene Therapy for Parkinson's Disease

Active, not recruiting·BBrain Neurotherapy Bio, Inc.·Phase 1·NCT04167540·11 enrolled

Parkinson disease1 trial

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Active, not recruiting·AAskBio Inc·Phase 2·NCT06285643·127 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AAV2-GDNF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AAV2-GDNF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AAV2-GDNF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Brain Neurotherapy Bio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 2[1]
Company: BBrain Neurotherapy Bio, Inc.

Related News